Mirum Prepares to Seek Approval for Rare Liver Disease Therapy

Mirum Pharmaceuticals is advancing therapies for rare liver diseases. The company is preparing to file an application to seek marketing approval for its lead experimental therapy maralixibat for Alagille syndrome, a genetic disorder in which bile accumulates in the liver because of malformations of the bile ducts. We spoke to Chris Peetz, president and CEO of Mirum, about Alagille syndrome, its lead experimental therapy, and why the company also hopes to seek approval for the drug in the related rare disorder progressive familial intrahepatic cholestasis, or PFIC.